Consumer Goods, Devices and Contract Manufacturing

In late September 2024 the rains of Hurricane Helene flooded Baxter International's plant at North Cove, on the North Fork of the Catawba River near Marion in western North Carolina. It was not an ordinary factory. North Cove made about 60% of the intravenous (IV) solutions produced in the United States (Virginia Department of Health and an analyst estimate, reported), about 1.5 million bags a day by the American Hospital Association's count, as well as peritoneal-dialysis fluids. Hospitals use IV fluids for almost every admission and keep days or weeks of stock, not months. Baxter put its customers on allocation, hospitals moved to conservation protocols, switching patients to oral hydration, pushing drugs rather than infusing them and using smaller bags, and the Food and Drug Administration allowed temporary imports from Baxter's plants abroad and from other makers (reported).

The recovery showed what a sterile plant is. Repairing the buildings was the easy part; each cleanroom, water-for-injection system and filling line had to be decontaminated, requalified and its first batches released. Baxter restarted its high-speed line, about a quarter of pre-storm output, at the end of October 2024; a second line in mid-November took the plant to about half; nearly all lines were running by 19 December 2024; and production returned to pre-hurricane levels in February 2025 (reported). The shortage outlasted the restart, because stock had to be rebuilt across the whole system. Baxter lifted allocations for virtually all IV-solution codes in mid-May 2025, and the FDA declared the national shortage of 0.9% sodium chloride over on 8 August 2025, about ten months after the flood.

Nobody had chosen the risk in a single decision. IV fluids are a low-price, high-volume product sold to hospitals through group purchasing contracts, and at those prices the efficient structure is a few very large plants with high-speed lines. A second North Cove would have cost a great deal for capacity that would sit idle in an ordinary year, and no contract paid for it. The concentration had been visible to supply-chain planners. It had not been priced by anyone.